Qilian International Holding Group Limited Asset Resilience Ratio

Latest as of March 2026: 0.01%

Qilian International Holding Group Limited asset resilience ratio. Qilian International Holding Group Limited (BGM) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Qilian International Holding Group Limit (BGM) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$28.40K
Cash + Short-term Investments

Total Assets

$436.55 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Qilian International Holding Group Limited (2018–2025)

Asset resilience ratio of Qilian International Holding Group Limited from 2018 to 2025. This chart shows how Qilian International Holding Group Limited's Asset Resilience Ratio has changed over time. Read total liabilities of Qilian International Holding Group Limit for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Qilian International Holding Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Qilian International Holding Group Limit assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $28.40K 0.01%
Total Liquid Assets $28.40K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Qilian International Holding Group Limited maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Qilian International Holding Group Limited Industry Peers by Asset Resilience Ratio

Compare Qilian International Holding Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Sandoz Group AG
SW:SDZ
Drug Manufacturers - Specialty & Generic 7.89%
H Lundbeck A/S
CO:HLUN-B
Drug Manufacturers - Specialty & Generic -0.56%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Viyash Scientific Limited
NSE:SEQUENT
Drug Manufacturers - Specialty & Generic 0.08%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%

Qilian International Holding Group Limited Asset Resilience Ratio by Year (2018–2025)

Qilian International Holding Group Limited asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Qilian International Holding Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-09-30 0.23% $994.89K $433.81 Million -15.47pp
2024-09-30 15.70% $8.32 Million $53.00 Million -13.45pp
2023-09-30 29.15% $14.94 Million $51.26 Million --
2022-09-30 0.00% $0.00 $64.53 Million --
2019-09-30 0.00% $0.00 $35.27 Million --
2018-09-30 0.04% $14.58K $33.34 Million --
pp = percentage points

About Qilian International Holding Group Limited

NASDAQ:BGM USA Drug Manufacturers - Specialty & Generic
Market Cap
$3.63 Billion
Market Cap Rank
#18835 Global
#4372 in USA
Share Price
$9.54
Change (1 day)
+0.00%
52-Week Range
$0.24 - $10.75
All Time High
$58.32
About

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and… Read more